Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and effectiveness of belimumab in adults with interstitial lung disease ILD linked to systemic sclerosis SSc and other connective tissue diseases CTD. This open-label extension study follows participants from previous clinical trials to assess whether belimumab can continue to slow lung function decline, disease progression, and improve quality of life over time. Participants will receive belimumab throughout the study. The research builds on earlier randomized trials, focusing on how well the drug is tolerated over several years. The study monitors participants over approximately five years, including key assessments at baseline and during follow-up visits. During the study, participants will be regularly assessed for adverse events and changes in lung function by measuring forced vital capacity FVC at set intervals, such as weeks 12, 26, and 52. Researchers will track safety outcomes and disease progression while participants either self-administer the medication or have it given by a caregiver or healthcare professional. The total participation duration may last up to around five years.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.
Actively Recruiting
Researchers are evaluating the Vsling device in patients with heart failure who have a reduced left ventricular ejection fraction and ventricular dilation. This prospective, multi-center, open-label clinical study aims to assess the feasibility, initial safety, and performance of the Vsling device as a treatment for this condition. The study is sponsored by Cardiac Success and is conducted as a phase 2 interventional trial. Participants will undergo implantation of the Vsling device, which is designed to repair the ventricle. The device is implanted via a catheter, and there is only one study group receiving this experimental intervention. The primary treatment period focuses on device implantation and monitoring. Throughout the study, participants will be closely monitored for device-related serious adverse events within 30 days after implantation. Assessments include echocardiographic evaluations, clinical status monitoring, and other safety observations. Participants will provide informed consent and be followed up for outcome measures and adverse events to evaluate device performance and safety over the course of the trial.